2023
NCOG-29. THE NEURO-ONCOLOGY MAGNITUDE OF CLINICAL BENEFIT SCALE (NEURO-MCBS) AS A COMPREHENSIVE AND CLINICALLY RELEVANT ASSESSMENT TOOL TO DETERMINE CLINICAL BENEFIT FROM TARGETED THERAPIES IN CNS TUMORS
Kurz S, Renovanz M, Rieger J, Bombach P, Grosse L, Rieger D, Hucker S, Hille H, Hippler M, Oener O, Ruhm K, Beha J, Malek H, Moeller Y, Bitzer M, Malek N, Tabatabai G. NCOG-29. THE NEURO-ONCOLOGY MAGNITUDE OF CLINICAL BENEFIT SCALE (NEURO-MCBS) AS A COMPREHENSIVE AND CLINICALLY RELEVANT ASSESSMENT TOOL TO DETERMINE CLINICAL BENEFIT FROM TARGETED THERAPIES IN CNS TUMORS. Neuro-Oncology 2023, 25: v220-v220. PMCID: PMC10639832, DOI: 10.1093/neuonc/noad179.0842.Peer-Reviewed Original ResearchProgression-free survivalCNS tumorsBrain metastasesTargeted therapyClinical benefitTherapy optionsFirst-line therapy optionTreatment efficacyDegree of clinical benefitClinical utilityMagnitude of Clinical Benefit ScaleNeuro-oncological conditionsSecondary CNS tumorsOutcome dataPhase I studyComprehensive molecular profilingOff-label therapyOutcome measuresAssessment of treatment efficacyClinical outcome dataAssess treatment efficacySurvival outcome dataPFS2/PFS1 ratioLongitudinal observational studyPerformance status
2022
Association of hyperglycemia and molecular subclass on survival in IDH-wildtype glioblastoma
Liu E, Vasudevaraja V, Sviderskiy V, Feng Y, Tran I, Serrano J, Cordova C, Kurz S, Golfinos J, Sulman E, Orringer D, Placantonakis D, Possemato R, Snuderl M. Association of hyperglycemia and molecular subclass on survival in IDH-wildtype glioblastoma. Neuro-Oncology Advances 2022, 4: vdac163. PMID: 36382106, PMCID: PMC9653172, DOI: 10.1093/noajnl/vdac163.Peer-Reviewed Original ResearchIDH-wt GBMAssociated with poor OSMethylation subclassesOverall survivalPoor OSIDH-wtMolecular subclassesRTK IAssociated with worse survivalAssociated with OSIDH-wildtype glioblastomaPotential survival benefitAssociation of hyperglycemiaAverage glucose valuesAverage glucoseStupp protocolDexamethasone doseMGMT statusSurvival benefitWorse survivalMesenchymal tumorsPerformance statusLow glucose levelsMGMT methylationMolecular subtypes